Our Company
Our mission is to change the standard of care for patients with immunologic and rare diseases. We are developing multiple novel biologic molecules toward this end.
Our lead late-stage clinical candidate is atacicept:
- Human TACI-Fc fusion protein that inhibits the two cytokines, BAFF and APRIL, that cause B cells to produce disease-causing antibodies
- Potential first-in-class dual BAFF/APRIL B cell modulator for IgA Nephropathy (IgAN), a B cell-mediated kidney disease that often progresses to kidney failure despite optimized supportive care
- ORIGIN Phase 2b long-term 96-week results consistent with IgAN disease modification
- ORIGIN 3, a pivotal Phase 3 clinical trial: primary endpoint met in June 2025
- Target profile: at-home self-administration by subcutaneous once weekly autoinjector
We hold worldwide global rights to MAU868:
- A monoclonal antibody that neutralizes infection by blocking BK virus (BKV) binding to host cells
- Phase 2 clinical trial showed MAU868 was well tolerated and showed clinically meaningful reductions in BK antiviral activity through 36 weeks in kidney transplant patients with BK viremia
- No BK-specific treatment currently available
- Target profile: monthly IV administration